Advertisement

22 Xerostomie: droge-mondsyndroom

Chapter
  • 839 Downloads

Samenvatting

Op grond van de experimentele gegevens kunnen de volgende conclusies worden getrokken:

  • Het is van cruciaal belang de oorzaak van de droge-mondklacht te diagnosticeren.

  • Indien de speekselklieren nog te stimuleren zijn, kan de droge-mondklacht bestreden worden met een smaak- of kauwstimulus of eventueel met een farmacon: supportive care.

  • Indien de speekselklieren niet meer te stimuleren zijn is de droge-mondklacht te bestrijden met een speekselsubstituut: palliative care.

  • Een speekselsubstituut op basis van mucinen voldoet beter in reologisch en bevochtigend opzicht dan de ontwikkelde speekselsubstituten op basis van CMC. Varkensmaagmucine lijkt geschikter dan runderspeekselmucine, maar een combinatie van beide mucinen is nog beter, eventueel gecombineerd met serumeiwitten.

  • Polymeren met zowel viskeuze als elastische eigenschappen, zoals de natuurlijke gommen (bijv. xanthaangom), worden door een aantal patiënten met xerostomie goed geaccepteerd. Speekselsubstituten op basis van xanthaangom lijken even effectief als speekselsubstituten op basis van dierlijke mucinen.

  • Het beste resultaat wordt veelal bereikt bij gebruik van de applicatie van een speekselsubstituut door middel van een spray en kauwtabletten. Voor een beperkte patiëntengroep is een applicatievorm (reservoir in een prothese) te maken die een continue bevochtiging van de mondholte gedurende gemiddeld vier uur mogelijk maakt.

  • Toevoeging van runderserumalbumine aan mucinebevattend speekselsubstituut kan leiden tot verlaging van het mucinegehalte en geeft verbetering van de reologische eigenschappen.

  • Nader onderzoek is gewenst naar een speekselsubstituut dat de mucosa verzacht, de orale microflora remt, de gebitselementen afdoende beschermt tegen demineralisatie en de orale functies bevordert.

  • Spoeldranken, mondsprays, mondgels en milde tandpasta’s met daarin verzachtende ingrediënten zoals olijfolie, betaïne of xylitol geven verlichting van xerostomie, die veroorzaakt wordt door het gebruik van meerdere geneesmiddelen (polyfarmacie; Ship e.a., 2007).

Literatuur

  1. Aframian D.J., M. Helcer, D. Livni en A. Markitziu. Pilocarpine for the treatment of salivary glands’ impairment caused by radioiodine therapy for thyroid cancer. Oral Dis. 12, (2006)297–300.PubMedGoogle Scholar
  2. Aframian D.J., M. Helcer, D. Livni, S.D.M. Robinson, A. Markitziu en C. Nadler. Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis. 13, (2007)88–92.PubMedGoogle Scholar
  3. Alajbeg I., N. Hladki, I.Z. Alajbeg, K. Rosin-Grget, V. Vucicevic-Boras en A Cekic-Arambasin. The treatment effects of pilocarpine in patients with xerostomia. Period. Biol. 107, (2005)201–206.Google Scholar
  4. Al-Hashimi I. The management of Sjögren’s syndrome in dental practice. J. Am. Dent. Ass. 132, (2001)1409–1417.PubMedGoogle Scholar
  5. Almståhl A. en M. Wikström. Electrolytes in stimulated whole saliva in individuals with hyposalivation of different origins. Archs. Oral Biol. 48, (2003)337–344.Google Scholar
  6. Almståhl A., M. Wikström, I. Stenberg, A. Jakobsson en B. Fagerberg-Mohlin. Oral microbiota associated with hyposalivation of different origins. Oral Microbiol. Immunol. 18, (2003)1–8.Google Scholar
  7. Alves M.B., A.C.F. Motta, W.C. Messina en D.A. Migliari. Saliva substitute in xerostomic patients with primary Sjögren’s syndrome: A single-blind trial. Quintessence Int. 35, (2004)392–396.PubMedGoogle Scholar
  8. Amerongen B.M. van en G.-J. van der Putten. Droge mond door medicijnengebruik? Ned. Tandartsenblad 57, (2002)837–839.Google Scholar
  9. Atkinson J.C. en P.C. Fox. Sjögren’s syndrome. Oral and dental considerations. J. Am. Dent. Ass. 124, (1993)74–86.PubMedGoogle Scholar
  10. Bardow A., J.M. ten Cate, B. Nauntofte en B. Nyvad. Effect of unstimulated saliva flow rate on experimental root caries. Caries Res. 37, (2003)232–236.PubMedGoogle Scholar
  11. Baum B.J., R.B. Wellner en C. Zheng. Gene transfer to salivary glands. Int. Rev. Cytol. 213, (2001 of 2002)93–146.PubMedGoogle Scholar
  12. Billings R.J., H.M. Proskin en M.E. Moss. Xerostomia and associated factors in a community-dwelling adult population. Commun. Dent. Oral Epidemiol. 24, (1996)312–316.Google Scholar
  13. Brun J.G., T.M. Madland en R. Jonsson. A prospective study of sicca symptoms in patients with rheumatoid arthritis. Arthritis Rheum. 49, (2003)187–192.PubMedGoogle Scholar
  14. Bultzingslowen I. von, T.P. Sollecito, P.C. Fox, T. Daniels, R. Jonsson, P.B. Lockhart, e.a. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodont. 103, (2007)S57–S65.Google Scholar
  15. Burlage F.R., R.P. Coppes, H. Meertens, M.A. Stokman en A. Vissink. Parotid and submandibular/ sublingual flow during high dose radiotherapy. Radiother. Oncol. 61, (2001)271–274.PubMedGoogle Scholar
  16. Chambers M.S., M. Posner, C.U. Jones, M.A. Biel, K.M. Hodge, R. Vitti, e.a. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, (2007)1102–1109.PubMedGoogle Scholar
  17. Coppes R.P., A. Vissink en A.W.T. Konings. Comparison of radiosensitivity of rat parotid and submandibular glands after different radiation schedules. Radiother. Oncol. 63, (2002)321–328.PubMedGoogle Scholar
  18. Cummins M.J., A. Papas, G.M. Kammer en P.C. Fox. Treatment of primary Sjögren’s syndrome with low-dose human interferon alfa administered by the oromucosa: combined phase III results. Arthritis Rheum. 49, (2003)585–593.PubMedGoogle Scholar
  19. Davies A.N., K. Broadley en D. Beighton. Salivary gland hypofunction in patients with advanced cancer. Oral Oncol. 38, (2002)680–685.PubMedGoogle Scholar
  20. Davies A.N., C. Daniels, R. Pugh en K. Sharma. A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Palliat. Med. 12, (1998)105–111.PubMedGoogle Scholar
  21. Dawidson I., B. Angmar-Mansson, M. Blom, E. Theodorsson en T. Lundeberg. Sensory stimulation (acupuncture) increases the release of vasoactive intestinal polypeptide in the saliva of xerostomia sufferers. Neuropeptides 32, (1998)543–548.PubMedGoogle Scholar
  22. Delporte C. en S. Steinfeld. Distribution and roles of aquaporins in salivary glands. Biochim. Biophys. Acta 1758, (2006)1061–1070.PubMedGoogle Scholar
  23. DiSabato-Mordarski T. en I. Kleinberg. Measurement and comparison of the residual saliva on various oral mucosal and dentition surfaces in humans. Archs Oral Biol. 41, (1996)655–665.Google Scholar
  24. Donatsky O., T. Johnson, P. Holmstrup en U. Bertram. Effect of saliment on parotid salivary gland secretion and xerostomia caused by Sjögren’s syndrome. Scand. J. Dent. Res. 90, (1982)157–162.PubMedGoogle Scholar
  25. Duxbury A.J., N.F. Hayes, N.S. Thakkar, D.G. Wastell, A. Kelly en F.N. Leach. Clinical trial of a mucin-containing artificial saliva. IRCS Med. Sci. 13, (1985)1197–1198.Google Scholar
  26. Edgar W.M., W.H. Bowen en M.F. Cole. Protein components in saliva and plaque fluid from irradiated primates. J. Oral Pathol. 11 (1982)252–259.PubMedGoogle Scholar
  27. Eeden L. van, H. Brand en A. van Nieuw Amerongen. Schirmer-test als meetmethode voor hyposialie. Ned. Tandartsenblad 62, (2007)30–31.Google Scholar
  28. Eisbruch A., N. Rhodus, D. Rosenthal, B. Murphy, C. Rash, S. Sonis, e.a. How should we measure and report radiotherapy-induced xerostomia? Sem. Radiat. Oncol. 13, (2003)226–234.Google Scholar
  29. Eisbruch A., N. Rhodus, D. Rosenthal, B. Murphy, C. Rash, S. Sonis, C. Scarantino en D. Brizel. The prevention and treatment of radiotherapy-induced xerostomia. Sem. Radiat. Oncol. 13, (2003)302–308.Google Scholar
  30. Epstein J.B., S. Emerton, D.A. Kolbinson, N.D. Le, N. Phillips, P. Stevenson-Moore, e.a. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 21, (1999)1–11.PubMedGoogle Scholar
  31. Epstein J.B., S. Emerton, N.D. Le en P. Stevenson-Moore. A double-blind crossover trial of Oral Balance gel and Biotène toothpaste versus placebo in patients with xerostomia following radiation therapy. Eur. J. Cancer 35, (1999)132–137.Google Scholar
  32. Field E.A., L.P. Longman, R. Bucknall, S.B. Kaye, S.M. Higham enW.M. Edgar. The establishment of a xerostomia clinic: a prospective study. Br. J. Oral Maxillfac. Surg. 35, (1997)96–103.Google Scholar
  33. Fox P.C., M.J. Cummins en J.M. Cummins. A third study on the use of orally administered anhydrous crystalline maltose for relief of dry mouth in primary Sjögren’s syndrome. J. Altern. Complem. Med. 8, (2002)651–659.Google Scholar
  34. Frost P.M., P.J. Shirlaw, J.D. Walter en S.J. Challacombe. Patient preferences in a preliminary study comparing an intra-oral lubricating device with the usual dry mouth lubricatring methods. Br. Dent. J. 193, (2002)403–408.PubMedGoogle Scholar
  35. Frydrych A.M., G.R. Davies, L.M. Slack-Smith en J. Heywood. An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia. Austr. Dent. J. 47, (2002)249–253.Google Scholar
  36. Gelhard T.B.F.M., V. Fidler, E.J. ’s-Gravenmade en A. Vissink. Remineralization of softened human enamel in mucin- or CMC-containing artificial saliva. J. Oral Pathol. 12, (1983)336–341.PubMedGoogle Scholar
  37. Gibson J., J.A. Halliday, K. Ewert en S. Robertson. A controlled release pilocarpine buccal insert in the treatment of Sjögren’s syndrome. Br. Dent. J. 202, (2007)1–6.Google Scholar
  38. Gorsky M., J.B. Epstein, J. Parry, M.S. Epstein, N.D. Le en S. Silverman. The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 97, (2004)190–195.PubMedGoogle Scholar
  39. Guggenheimer J. en P.A. Moore. Xerostomia – Etiology, recognition and treatment. J. Am. Dent. Ass. 134, (2003)61–69.PubMedGoogle Scholar
  40. Hamada T., T. Nakane, T. Kimura, K. Arisawa, K. Yoneda, T. Yamamoto, e.a. Treatment of xerostomia with the bile secretion stimulating drug anethole trithione: a clinical trial. Am. J. Med. Sci. 318, (1999)146–151.PubMedGoogle Scholar
  41. Hendrickson R.G., A.P. Morocco en M.I. Greenberg. Pilocarpine toxicity and the treatment of xerostomia. J. Emergency Med. 26, (2003)429–432.Google Scholar
  42. Hyer S., A. Kong, B. Pratt en C. Harmer. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin. Oncol. 19, (2007)83–86.Google Scholar
  43. Inoue N., H. Iida, Z. Yuan, Y. Ishikawa en H. Ishida. Age-related decreases in the response of aquaporin- 5 to acetylcholine in rat parotid glands. J. Dent. Res. 82, (2003)476–480.PubMedGoogle Scholar
  44. Ishikawa Y., Z. Yuan, N. Inoue, M.T. Skowronski, Y. Kakae, M. Shono, e.a. Identification of AQP5 in lipid rafts and its trasnlocation to apical membranes by activation of M3 mAChRs in interlobular ducts of rat parotid gland. Am. J. Physiol. Cell Physiol. 289, (2005)C1303–C1311.PubMedGoogle Scholar
  45. Ivoren Kruis. Brochure: Droge mond. Praktische adviezen voor behandelaars van patiënten met een droge mond. 2007.Google Scholar
  46. Jager-Wittenaar H., A. Vissink, R. van Weissenbruch en A. van Nieuw Amerongen. Voeding bij smaaken reukstoornissen. In: M. Former, J. Van Duinen en R. Van Nuland (red). Informatorium Voeding en Diëtetiek. Dieetleer XXVIIa-1 - XXVIIa29. Bohn Stafleu van Loghum, Houten, 2002.Google Scholar
  47. Jansma J. Oral sequelae resulting from head and neck radiotherapy. Dissertatie, Rijksuniversiteit Groningen, 1991.Google Scholar
  48. Jansma J., A. Vissink, W.K. Jongebloed en E.J. ’s-Gravenmade. Xerostomie-gerelateerde cariës. Ned. Tijdschr. Tandheelkd. 99, (1992)225–232.PubMedGoogle Scholar
  49. Jedel E. Acupuncture in xerostomia – a systematic review. J. Oral Rehabil. 32, (2005)392–396.PubMedGoogle Scholar
  50. Jensen J.L., T. Uhlig, T.K. Kvien en T. Axell. Characteristics of rheumatoid arthritis patients with selfreported sicca symptoms: evaluation of medical, salivary and oral parameters. Oral Dis. 3, (1997)254–261.PubMedGoogle Scholar
  51. Jensen S.B., A.M. Pedersen, J. Reibel en B. Nauntofte. Xerostomia and hypofunction of the salivary glands in cancer therapy. Supp. Care Canc. 11, (2003)207–225.Google Scholar
  52. Kam A.Y.L., A.S. McMillan, E.H.N. Pow, K.C.M. Leung en H.W.K. Luk. A preliminary report on patient acceptance of a novel intra-oral lubricating device for the management of radiotherapy-related xerostomia. Clin. Oral Invest. 9, (2005)148–153.Google Scholar
  53. Khosravani N., J. Ekström en D. Birkhed. Intraoral stimulation of salivary secretion with the cholinesterase inhibitor physostigmine as a mouth spray: A pilot study in healthy volunteers. Archsoral Biol. 52, (2007)1097–1101.Google Scholar
  54. Kirstilä V., M. Lenander-Lumikari en J. Tenovuo. Effects of a lactoperoxidase system-containing toothpaste on dental plaque and whole saliva in vivo. Acta Odontol. Scand. 52, (1994)346–353.PubMedGoogle Scholar
  55. Kirstilä V., M. Lenander-Lumikari, E. Söderling en J. Tenovuo. Effects of oral hygiene products containing lactoperoxidase, lysozyme and lactoferrin on the composition of whole saliva and on subjective oral symptoms in patients with xerostomia. Acta Odontol. Scand. 54, (1996)391–397.PubMedGoogle Scholar
  56. Leung K.C.M., A.S. McMillan, M.C.M. Wong, W.K. Leung, M.Y. Mok en C.S. Lau. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren’s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin. Rheumatol. 27, (2008)429–436.PubMedGoogle Scholar
  57. Li J., S. Lee, S.-Y. Choi, S.J. Lee, S.-B. Oh, J.-H. Lee, e.a. Effects of pilocarpine on the secretory acinar cells in human submandibular glands. Life Sci. 79, (2006)2441–2447.PubMedGoogle Scholar
  58. Lockhart P.B., P.C. Fox, A.C. Gentry, R. Acharya en H.J. Norton. Pilot study of controlled-release pilocarpine in normal subjects. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodont. 82, (1996)517–524.Google Scholar
  59. Logemann J.A., B.R. Pauloski, A.W. Rademaker, C.L. Lazarus, B. Mittal, J. Gaziano, e.a. Xerostomia: 12- month changes in saliva production and its relationship to perception and performance of swallow function, oral intake, and diet after chemoradiation. Head Neck 25, (2003)432–437.PubMedGoogle Scholar
  60. Lopez-Jornet P., F. Camacho-Alonso en A. Bermejo-Fenoll. A simple test for salivary gland hypofunction using oral Schirmer’s test. J. Oral Pathol. Med. 35, (2006)244–248.PubMedGoogle Scholar
  61. Maier H. en M. Tisch. Xerostomia and burning sensation of the oral mucosa: causes and treatment options. HNO 51, (2003)739–747.PubMedGoogle Scholar
  62. Mariette X. Current and potential treatments for primary Sjögren’s syndrome. Joint Bone Spine 69, (2002)363–366.PubMedGoogle Scholar
  63. Masyuk A.I., R.A. Marinelli en N.F. Larusso. Water transport by epithelia of the digestive tract. Gastroenterology 122, (2002)545–562.PubMedGoogle Scholar
  64. Mendoza A.R. en M.J. Tomlison. The split denture: A new technology for artificial saliva reservoirs in mandibular dentures. Austr. Dent. J. 48, (2003)190–194.Google Scholar
  65. Mendoza A., B. Shaffer, D. Karakla, M.E. Mason, D. Elkins en T.E. Goffman. Quality of life with welldifferentiated thyroid cancer: treatment toxicities and their reduction. Thyroid 14, (2004)133–140.PubMedGoogle Scholar
  66. Merwe J.P. van de. Het syndroom van Sjögren. Bureau PAOG Erasmus Universiteit Rotterdam, 1993.Google Scholar
  67. Mese H. en R. Matsuo. Salivary secretion, taste and hyposalivation. Invited review. J. Oral Rehabil. 34, (2007)711–723.Google Scholar
  68. Michels L.F.E. Droge mond en speekselvloed. In: Handboek Tandheelkundige Praktijk, 1986, (B7. 5–3,11).Google Scholar
  69. Momm F. en R. Guttenberger. Treatment of xerostomia following radiotherapy: does age matter? Supp. Care Cancer 10, (2002)505–508.Google Scholar
  70. Mouly S., M. Salom, Y. Tillet, A.C. Coudert, F. Oberli, P.M. Preshaw, e.a. Management of xerostomia in older patients - A randomised controlled trial evaluating the efficacy of a new oral lubricant solution. Drugs Aging 24, (2007)957–965.PubMedGoogle Scholar
  71. Moutsopoulos N.M. en H.M. Moutsopoulos. Therapy of Sjögren’s syndrome. Springer Semin. Immunopathol. 23, (2001)131–145.PubMedGoogle Scholar
  72. Nagler R.M. en A. Nagler. Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-hostdisease: a sialometric study. Bone Marrow Transpl. 23, (1999)1007–1011.Google Scholar
  73. Nagy K., E. Urban, O. Fazekas, L. Thurzo en E. Nagy. Controlled study of lactoperoxidase gel on oral flora and saliva in irradiated patients with oral cancer. J. Craniofacial Surg. 18, (2007)1157–1164.Google Scholar
  74. Navazesh M. How can oral health care providers determine if patients have dry mouth. J. Am. Dent. Ass 134, (2003)613–620.Google Scholar
  75. Nederfors T., R. Isaksson, H. Mörnstad en C. Dahlöf. Prevalence of perceived symptoms of dry mouth in an adult Swedish population – Relation to age, sex and pharmacotherapy. Commun. Dent. Oral Epidemiol. 25, (1997)211–216.Google Scholar
  76. Nieuw Amerongen A. van, C.P. Bots en A.W. van de Beld. Een natte mond en toch een droog gevoel. Ned. Tandartsenblad 56, (2001)580–583.Google Scholar
  77. Nieuw Amerongen A. van. Hyposalivatie en slikproblemen. Logopedie en Foniatrie 74, 2002)66–69.Google Scholar
  78. Nieuw Amerongen A. van en E.C.I. Veerman. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support. Care Cancer 11, (2003)226–231.PubMedGoogle Scholar
  79. Nusair S. en A. Rubinow. The use of oral pilocarpine in xerostomia and Sjögren’s syndrome. Sem. Arthritis Rheum. 28, (1999)360–367.Google Scholar
  80. Ohrn K.E., Y.B. Wahlin en P.O. Sjoden. Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support. Care Cancer 9, (2001)247–257.PubMedGoogle Scholar
  81. Omori Y., T. Asari, K. Maruyama, H. Kusama, M. Kojima en N. Shibata. Effects of pilocarpine hydrochloride and cevimeline on submandibular/ sublingual salivation in rat xerostomia model produced by x-ray irradiation. Arzneimittel-Forschung-Drug Res. 53, (2003)342–350.Google Scholar
  82. Orellana M.F., M.O. Lagravère, D.G.J. Boychuk, P.W. Major, C. Flores-Mir en C. Ortho. Prevalence of xerostomia in population-based samples: a systematic review. J. Publ. Hlth Dent. 66, (2006)152–158.Google Scholar
  83. Papas A.S., Y.S. Sherrer, M. Charney, H.E. Golden, T.A. Medsger, B.T. Walsh, e.a. Successful treatment of dry mouth and dry eye symptoms in Sjögren’s syndrome patients with oral pilocarpine. J. Clin. Rheumatol. 10, (2004)169–177.PubMedGoogle Scholar
  84. Peluso G., M. De Santis, R. Inzitari, C. Fanali, T. Cabras, I. Messana, e.a. Proteomic study of salivary peptides and proteins in patients with Sjögren’s syndrome before and after pilocarpine treatment. Arthritis Rheum. 56, (2007)2216–2222.PubMedGoogle Scholar
  85. Pijpe J., G.W. van Imhoff, F.K.L. Spijkervet, J.L.N. Roodenburg, G.J. Wolbink, K. Mansour, e.a. Rituximab treatment in patients with primary Sjögren’s syndrome. Arthritis Rheum. 52, (2005)2740–2750.PubMedGoogle Scholar
  86. Porter S.R., C. Scully en A.M. Hegarty. An update of the etiology and management of xerostomia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 97, (2004)28–46.PubMedGoogle Scholar
  87. Ramos-Casals M. en P. Brito-Zeron. Emerging biological therapies in primary Sjögren’s syndrome. Rheumatology 46, (2007)1389–1396.PubMedGoogle Scholar
  88. Rassing M.R. Chewing gum as a drug delivery system. Adv. Drug Deliv. Rev. 13, (1994)89–121.Google Scholar
  89. Regelink G., A. Vissink, H. Reintsema en J.M. Nauta. Efficacy of a synthetic polymer based saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int. 29, (1998).383–388.PubMedGoogle Scholar
  90. Reich E., L.G. Petersson, L. Netuschil en M. Brecx. Mouthrinses and dental caries. Int. Dent. J. 52, (2002)337–345.Google Scholar
  91. Reijden W.A. van der. De reologie van speeksel: een biochemofysisch probleem. Doctoraalscriptie, V.U., ACTA, Amsterdam, 1992; zie Ned. Tijdschr. voor Tandh. 100, (1993)351–354.Google Scholar
  92. Reijden W.A. van der, E.C.I. Veerman en A. van Nieuw Amerongen. Shear rate dependent viscoelastic behaviour of human glandular salivas. Biorheology 30, (1993)141–152.PubMedGoogle Scholar
  93. Reijden W.A. van der, H. van der Kwaak, A. Vissink, E.C.I. Veerman en A. van Nieuw Amerongen. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren’s syndrome. Arthritis Rheum. 39, (1996)57–69.PubMedGoogle Scholar
  94. Reijden W.A. van der, M.J. Buijs, J.J. Damen, E.C.I. Veerman, J.M. ten Cate en A. van Nieuw Amerongen. Influence of polymers for use in saliva substitutes on de- and remineralization of enamel in vitro. Caries Res. 31, (1997)216–223.PubMedGoogle Scholar
  95. Ring T., M. Kallenbach, J. Praetorius, S. Nielsen en B. Melgaard. Successful treatment of a patient with primary Sjögren’s syndrome with Rituximab. Clin. Rheumatol. 25, (2006) 891–894.PubMedGoogle Scholar
  96. Roesink J.M., M.A. Moerland, J.J. Battermann, G.J. Hordijk en C.H. Terhaard. Quantitative dosevolume response analysis of changes in parotid gland function after radiotherapy in the head-andneck region. Int. J. Radiat. Oncol. Biol. Phys. 51, (2001)938–946.PubMedGoogle Scholar
  97. Russell S.L. en S. Reisine. Investigation of xerostomia in patients with rheumatoid arthritis. J. Am. Dent. Ass. 129, (1998)733–739.PubMedGoogle Scholar
  98. Rydholm M. Acupuncture for patients in hospitalbased home care suffering from xerostomia. J. Palliat. Care 15, (1999)20–23.PubMedGoogle Scholar
  99. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 9, (2003)165–176.PubMedGoogle Scholar
  100. Seve P., E. Gachon, P. Petiot, K. Stankovic, A. Charhon en C. Broussolle. Successful treatment with rituximab in a patient with mental nerve neuro-pathy in primary Sjögren’s syndrome. Rheum. Int. 28, (2007)175–177.Google Scholar
  101. Shahdad S.A., C. Taylor, S.C. Barclay, I.N. Steen en P.M. Preshaw. A double-blind, crossover study of Biotène Oral Balance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur. J. Cancer Care 14, (2005)319–326.Google Scholar
  102. Shiboski C.H., T.A. Hodgson, J.A. Ship en M. Schiodt. Management of salivary hypofunction during and after radiotherapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 103, (2007)S66.e1–S66.e19.Google Scholar
  103. Ship J.A. en D.J. Fisher. The relationship between dehydration and parotid salivary gland function in young and older healthy adults. J. Gerontol. Med. Sci. 52A, (1997)M310–M319.Google Scholar
  104. Ship J.A., J.A. McCutcheon, S. Spivakovsky en A.R. Kerr. Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J. Oral Rehabil. 34, (2007)724–732.PubMedGoogle Scholar
  105. Sinclair G.F., P.M. Frost en J.D. Walter. New design for an artificial saliva reservoir for the mandibular complete denture. J. Prosthet. Dent. 75, (1996)276–280.PubMedGoogle Scholar
  106. Smith G., A.J. Smith, L. Shaw enM.J. Shaw. Artificial saliva substitutes and mineral dissolution. J. Oral Rehabil. 28, (2001)72731.Google Scholar
  107. Soto- A., E. Rojas en A. Kraus. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. Archs. Med. Res. 33, (2002)95–106.Google Scholar
  108. Sreebny L.M., W.-X. Zhu, S.S. Schwartz en A.G. Meek. The preparation of an autologous saliva for use with patients undergoing therapeutic radiation for head and neck cancer. J. Oral Maxillofac. Surg. 53, (1995)131–139.PubMedGoogle Scholar
  109. Steenberghe D. van, E. van den Eynde, R. Jacobs en M. Quirynen. Effect of a lactoperoxidase containing tooth paste in radiation-induced xerostomia. Int. Dent. J. 44, (1994)133–138.PubMedGoogle Scholar
  110. Steinfeld S.D., P. Demols, I. Salmon, R. Kiss en T. Appelboom. Infliximab in patients with primary Sjögren’s syndrome. A pilot study. Arthritis Rheum. 44, (2001)2371–2375.PubMedGoogle Scholar
  111. Suh K.-I., J.-Y. Lee, J.-W. Chung, Y.-K. Kim en H.-S. Kho. Relationship between salivary flow rate and clinical symptoms and behaviours in patients with dry mouth. J. Oral Rehabil. 34, (2007)739–744.PubMedGoogle Scholar
  112. Sung J.-M., S.-Kuo, H.-R. Guo, S.-F. Chuang, S.-Y. Lee en J.-J. Huang. Decreased salivary flow rate as a dipsogenic factor in hemodialysis patients: Evidence from an observational study and a pilocarpine clinical trial. J. Am. Soc. Nephrol. 16, (2005)3418–3429.PubMedGoogle Scholar
  113. Suzuki K., M. Matsumoto, M. Nakashima, K. Takada, T. Nakanishi, M. Okada, e.a. Effect of cevimeline on salivary components in patients with Sjögren’s syndrome. Pharmacology 74, (2005)100–105.PubMedGoogle Scholar
  114. Sweeney M.P., J. Bagg,W.P. Baxter en T.C. Aitchison. Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients. Palliat. Med. 11, (1997)225–232.PubMedGoogle Scholar
  115. Taylor S.E. Efficacy and economic evaluation of pilocarpine in treating radiation-induced xerostomia Expert Opin. Pharmacother. 4, (2003)1489–1497.Google Scholar
  116. Tenovuo J. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety. Oral Dis. 8, (2002)23–29.PubMedGoogle Scholar
  117. Tschoppe P., H. Meyer-Lueckel, R. Toll en A.M. Kielbassa. In vitro analysis of an new saliva substitute (Saliva natura) on enamel and dentin. Laryngo-Rhino-Otologie 86, (2007)723–727.PubMedGoogle Scholar
  118. Tsubota K., S. Hirai, L.S. King, P. Agre en N. Ishida. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren’s syndrome. The Lancet 357, (2001)688–689.Google Scholar
  119. Valdez J.H., A. Wolff, J.C. Atkinson, A.A. Macynski en P.C. Fox. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 17, (1993)1848–1851.Google Scholar
  120. Visch L.L., E.J. ’s-Gravenmade, R.M.H. Schaub, W.L.J. van Putten en A. Vissink. A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. Int. J. Oral Maxillofac. Surg. 15, (1986)395–400.PubMedGoogle Scholar
  121. Vissink A., E.J. ’s-Gravenmade, A.K. Panders, A. Vermey, J.K. Petersen, L.L. Visch, e.a. A clinical comparison between commercially available mucinand CMC-containing saliva substitutes. Int. J. Oral Surg. 12, (1983)232–238.PubMedGoogle Scholar
  122. Vissink A., H.A. Waterman, E.J. ’s-Gravenmade, A.K. Panders en A. Vermey. Rheological properties of saliva substitutes containing mucin, carboxymethylcellulose or polyethylenoxide. J. Oral Pathol. 13, (1984)22–28.PubMedGoogle Scholar
  123. Vissink A., E.J. ’s-Gravenmade, T.B.F.M. Gelhard, A.K. Panders en M.H. Franken. Rehardening properties of mucin- or CMC-containing saliva substitutes on softened human enamel. Caries Res. 19, (1985)212–218.PubMedGoogle Scholar
  124. Vissink A. Xerostomia. Development, properties and application of a mucin-containing saliva substitute. Dissertatie, Rijksuniversiteit Groningen, 1985.Google Scholar
  125. Vissink A., H.P. de Jong, H.J. Busscher, J. Arends en E.J. ’s-Gravenmade. Wetting properties of human saliva substitutes. J. Dent. Res. 65, (1986)1121–1124.PubMedGoogle Scholar
  126. Vissink A., R.M.H. Schaub, L.J. van Rijn, E.J. ’s-Gravenmade, A.K. Panders en A. Vermey. The efficacy of mucin-containing artificial saliva in alleviating symptoms of xerostomia. Gerodontology 6, (1987)95–101.PubMedGoogle Scholar
  127. Vissink A., J. Jansma en E.J. ’s-Gravenmade. Oorzaak, gevolg en behandeling van hyposialie. Ned. Tijdschr. Tandheelkd. 99, (1992)92–96.PubMedGoogle Scholar
  128. Vissink A., A. van Nieuw Amerongen, H. Wesseling en E.J. ’s-Gravenmade. De droge mond. De mogelijk oorzakelijke rol van geneesmiddelen. Ned. Tijdschr. Tandheelkd. 99, (1992)103–111.PubMedGoogle Scholar
  129. Vissink A. en F.K.L. Spijkervet. Monddroogheid als gevolg van medicijngebruik, het syndroom van Sjögren en radiotherapie. In: A.F. Käyser, C.E.L. en A.J. de Gee (red). Het Tandheelkundig Jaar 1998(51– 72). Bohn Stafleu Van Loghum, Houten.Google Scholar
  130. Vissink A., J. Jansma, F.K.L. Spijkervet, F.R. Burlage en R.P. Coppes. Oral sequelae of head and neck radiotherapy. Crit. Rev. Oral Biol. Med. 14, (2003)199–212.PubMedGoogle Scholar
  131. Vissink A., F.R. Burlage, F.K.L. Spijkervet, J. Jansma en R.P. Coppes. Prevention and treatment of the consequences of head and neck radiotherapy. Crit. Rev. Oral Biol. Med. 14, (2003):213–225.Google Scholar
  132. Vissink A., W.W.I. Kalk, K. Mansour, F.K.L. Spijkervet, H. Bootsma, J.L.N. Roodenburg, e.a. Comparison of lacrimal and salivary gland involvement in Sjögren’s syndrome. Archs Otolaryngol. Head Neck Surg. 129, (2003)966–971.Google Scholar
  133. Walter M.A., C.P. Turtschi, C. Schindler, P. Minnig, J. Müller-Brand en. B. Müller. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: Long-term results of a longitudinal cohort study. J. Nucl. Med. 48, (2007)1620–1625.PubMedGoogle Scholar
  134. Wasnich R., S. Gallagher, S. Stanek, J.R. MacDonald, G. Balan, Y. Omori, e.a. Salivary flow rates and pharmacokinetics in healthy Japanese and Caucasian volunteers administered oral pilocarpine. Clin. Drug Invest. 23, (2003)411–417.Google Scholar
  135. Wolff M.S. en I. Kleinberg. Oral mucosal wetness in hypo- and normosalivators. Archs Oral Biol. 43, (1998)455–462.Google Scholar
  136. Wolff M.S. en I. Kleinberg. The effect of ammonium glycopyrrolate (Robinul R)-induced xerostomia on oral mucosal wetness and flow of gingival crevicular fluid in humans. Archs Oral Biol. 44, (1999)97–102.Google Scholar
  137. Wolinsky L.E., B. Seto en R. Cerveny. Effect of saliva substitutes upon binding of selected oral bacteria to hydroxyapatite. Caries Res. 19, (1985)507–511.PubMedGoogle Scholar
  138. Yarat A., S. Akyüz, L. Koc, H. Erdem en N. Emekli. Salivary sialic acid, protein, salivary flow rate, pH, buffering capacity and caries indices in subjects with Down’s syndrome. J. Dent. 27, (1999)115–118.PubMedGoogle Scholar
  139. Zettinig G., G. Hanselmayer, B.J. Fueger, A. Hofmann, C. Pirich, J. Nepp, e.a. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur. J. Nucl. Med. 29, (2002)1428–1432.Google Scholar

Copyright information

© Bohn Stafleu van Loghum, onderdeel van Springer Uitgeverij 2008

Authors and Affiliations

  1. 1.Sectie Orale BiochemieAcademisch Centrum Tandheelkunde Amsterdam (ACTA), Vrije Universiteit en Universiteit van AmsterdamAmsterdam

Personalised recommendations